Market Overview

Goldman Sachs Calls Allergan (AGN) Top Idea


Goldman Sachs analysts Randall Stanicky, Gregory Waterman and Stephan Stewart maintained their CL-Buy rating for shares of Allergan Inc (NYSE: AGN)

The analysts said that their meetings with physicians confirmed improving demand trends and said that Allergan Inc remains one of their top investing ideas.

The Goldman Sachs analysts wrote, "AGN remains our top idea with data points supporting near-term upside revision with Botox migraine approval a meaningful catalyst. We make no change to EPS which reflects a 17% 3-year CAGR (that would move higher upon migraine approval given risk adjustment) against a 15.7x 2011 EPS on pull-back. Our 12m $78 TP (P/E, EV/EBITDA, and M&A premium) implies 35% upside."

Posted-In: Goldman Sachs Gregory Waterman Randall Stanicky Stephan StewartAnalyst Color Analyst Ratings


Related Articles (AGN)

View Comments and Join the Discussion!

Latest Ratings

POWLSidoti & Co.Maintains47.0
XDeutsche BankInitiates Coverage On121.0
WTEBMO CapitalMaintains18.0
DOLBMO CapitalMaintains50.0
NABMO CapitalMaintains69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Benzinga's Daily Reading List

ShoreBank Lines Up Financing, But is it Enough?